Liste modèle des médicaments essentiels

Amikacin

Section	Indications
Access group antibiotics ◦ Parenteral > General injections > unspecified: 50 mg per mL in 2 mL vial (as sulfate); 250 mg per mL in 2 mL vial (as sulfate) ◦ Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate); 50 mg per mL in 2 mL vial (as sulfate) ◦ Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)	**Premier choix** Neutropaenia (high-risk) co-prescrite avec cefotaxime Acute pyelonephritis (severe) co-prescrite avec cefotaxime Inflammatory or other diseases of prostate (severe) co-prescrite avec ceftriaxone Acute pyelonephritis (severe) co-prescrite avec ceftriaxone Inflammatory or other diseases of prostate (severe)

Amoxicillin

Section	Indications
Access group antibiotics ◦ Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid ◦ Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection ◦ Oral > Solid > dispersible tablet: 250 mg (scored) (as trihydrate); 500 mg (scored) (as trihydrate) ◦ Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate) ◦ Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate); 1 g (as trihydrate) ◦ Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid	**Premier choix** Acute pharyngitis Periapical abscess without sinus Acute sinusitis Acute otitis media Chronic obstructive pulmonary disease with acute exacerbation Acute malnutrition in infants, children or adolescents (uncomplicated) [children] Acute malnutrition in infants, children or adolescents (complicated) [children] Bacterial pneumonia (Community-acquired pneumonia - mild to moderate) Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescrite avec gentamicin Sepsis without septic shock **Second choix** Bacterial meningitis **Autres indications** Bacterial infection of unspecified site Infectious cystitis

Amoxicillin + clavulanic acid

Section	Indications
Access group antibiotics ◦ Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection ◦ Oral > Liquid: 125 mg (as trihydrate) + 31.25 mg (as potassium salt) / 5 mL powder for oral liquid; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid ◦ Oral > Solid > dispersible tablet: 200 mg (as trihydrate) + 28.5 mg (as potassium salt); 250 mg (as trihydrate) + 62.5 mg (as potassium salt) ◦ Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt); 875 mg (as trihydrate) + 125 mg (as potassium salt) ◦ Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)	**Premier choix** Bacterial pneumonia (Community-acquired pneumonia - severe) [children] Acute sinusitis Other specified pneumonia (Hospital-acquired pneumonia) Chronic obstructive pulmonary disease with acute exacerbation Neutropaenia (low-risk) Peritoneal abscess (mild-moderate) Peritonitis (mild-moderate) Infectious cystitis Bacterial cellulitis, erysipelas or lymphangitis **Second choix** Bacterial pneumonia (Community-acquired pneumonia - mild to moderate) Bacterial pneumonia (Community-acquired pneumonia - severe) Bacterial infection of joint Acute otitis media Other specified prophylactic measures Osteomyelitis or osteitis **Autres indications** Bacterial infection of unspecified site

Ampicillin

Section	Indications
Access group antibiotics ◦ Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection ◦ Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral suspension ◦ Oral > Solid: 250 mg (anhydrous); 500 mg (anhydrous)	**Premier choix** Bacterial pneumonia (Community-acquired pneumonia - severe) [children] Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescrite avec gentamicin Sepsis without septic shock co-prescrite avec gentamicin Peritoneal abscess (mild-moderate) co-prescrite avec gentamicin Peritoneal abscess (severe) co-prescrite avec gentamicin Peritonitis (mild-moderate) co-prescrite avec gentamicin Peritonitis (severe) **Second choix** Bacterial meningitis **Autres indications** Bacterial infection of unspecified site

Benzathine benzylpenicillin

Section	Indications
Access group antibiotics ◦ Parenteral > General injections > IM: 1.2 million IU in vial (≈ 900 mg) powder for injection; 2.4 million IU in vial (≈ 1.8 g) powder for injection	**Premier choix** Congenital syphilis [children] Syphilis **Autres indications** Bacterial infection of unspecified site

Benzylpenicillin

Section	Indications
Access group antibiotics ◦ Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt) ◦ Parenteral > General injections > unspecified: 600 mg in vial powder for injection (= 1 million IU as sodium or potassium salt); 3 g in vial powder for injection (= 5 million IU as sodium or potassium salt)	**Premier choix** Bacterial pneumonia (Community-acquired pneumonia - severe) [children] Acute malnutrition in infants, children or adolescents (complicated) [children] Congenital syphilis [children] Syphilis co-prescrite avec gentamicin Sepsis without septic shock **Second choix** Bacterial meningitis **Autres indications** Bacterial infection of unspecified site

Cefalexin

Section	Indications
Access group antibiotics ◦ Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid ◦ Oral > Solid: 250 mg (as monohydrate); 500 mg (as monohydrate) ◦ Oral > Solid > dispersible tablet: 125 mg; 250 mg ◦ Oral > Solid: 250 mg (as monohydrate)	**Premier choix** Bacterial cellulitis, erysipelas or lymphangitis **Second choix** Chronic obstructive pulmonary disease with acute exacerbation Acute pharyngitis **Autres indications** Bacterial infection of unspecified site

Cefazolin

Section	Indications
Access group antibiotics ◦ Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection	**Premier choix** Other specified prophylactic measures co-prescrite avec metronidazole Other specified prophylactic measures **Second choix** Bacterial infection of joint Osteomyelitis or osteitis **Autres indications** Surgical site infection

Chloramphenicol

Section	Indications
Access group antibiotics ◦ Parenteral > General injections > IV: 1 g in vial powder for injection (sodium succinate) ◦ Parenteral > General injections > IM: 500 mg in 2 mL ampoule oily suspension for injection ◦ Oral > Liquid: 150 mg per 5 mL (as palmitate) ◦ Oral > Solid: 250 mg capsule	**Second choix** Bacterial meningitis **Autres indications** Bacterial infection of unspecified site

Clindamycin

Section	Indications
Access group antibiotics ◦ Parenteral > General injections > IV: 150 mg per mL (as phosphate); 600 mg per 4 mL (as phosphate); 900 mg per 6 mL (as phosphate) ◦ Oral > Liquid: 75 mg per 5 mL powder for oral liquid (as palmitate hydrochloride) ◦ Oral > Solid: 150 mg (as hydrochloride) ◦ Oral > Liquid: 75 mg per 5 mL (as palmitate hydrochloride) ◦ Oral > Solid: 150 mg (as hydrochloride) capsule ◦ Parenteral > General injections > unspecified: 150 mg per mL (as phosphate) injection	**Premier choix** Necrotising fasciitis **Second choix** Bacterial infection of joint Osteomyelitis or osteitis **Autres indications** Bacterial infection of unspecified site

Cloxacillin

Section	Indications
Access group antibiotics ◦ Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid; 250 mg per 5 mL (as sodium salt) powder for oral liquid ◦ Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 250 mg in vial (as sodium salt) powder for injection ◦ Oral > Solid > capsule: 500 mg (as sodium salt); 1 g (as sodium salt); 250 mg (as sodium salt) ◦ Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid ◦ Oral > Solid: 500 mg (as sodium salt) capsule; 1 g (as sodium salt) capsule ◦ Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection	**Premier choix** Bacterial infection of joint Osteomyelitis or osteitis Bacterial cellulitis, erysipelas or lymphangitis **Second choix** Sepsis without septic shock **Autres indications** Bacterial infection of unspecified site

Dicloxacillin

Section	Indications
Access group antibiotics	**Premier choix** Therapeutic equivalent to cloxacillin pour Bacterial infection of joint Therapeutic equivalent to cloxacillin pour Osteomyelitis or osteitis Therapeutic equivalent to cloxacillin pour Bacterial cellulitis, erysipelas or lymphangitis **Second choix** Therapeutic equivalent to cloxacillin pour Sepsis without septic shock

Doxycycline

Section	Indications
Access group antibiotics ◦ Oral > Liquid: 25 mg per 5 mL powder for oral liquid (monohydrate); 50 mg per 5 mL (calcium) ◦ Parenteral > General injections > unspecified: 100 mg in vial powder for injection ◦ Oral > Solid > dispersible tablet: 100 mg (as monohydrate) ◦ Oral > Solid > dosage form: 50 mg (as hyclate); 100 mg (as hyclate) ◦ Oral > Solid > dosage form: 100 mg (as hyclate) ◦ Oral > Liquid: 25 mg per 5 mL (anhydrous); 50 mg per 5 mL (anhydrous) ◦ Oral > Solid: 100 mg (as hyclate); 50 mg (as hyclate)	**Premier choix** Cholera Chlamydia trachomatis **Second choix** Bacterial pneumonia (Community-acquired pneumonia - mild to moderate) Cholera [children] Chronic obstructive pulmonary disease with acute exacerbation **Autres indications** Bacterial infection of unspecified site

Flucloxacillin

Section	Indications
Access group antibiotics	**Premier choix** Therapeutic equivalent to cloxacillin pour Bacterial infection of joint Therapeutic equivalent to cloxacillin pour Osteomyelitis or osteitis Therapeutic equivalent to cloxacillin pour Bacterial cellulitis, erysipelas or lymphangitis **Second choix** Therapeutic equivalent to cloxacillin pour Sepsis without septic shock

Gentamicin

Section	Indications
Access group antibiotics ◦ Parenteral > General injections > unspecified: 10 mg per mL in 2 mL vial (as sulfate); 40 mg per mL in 2 mL vial (as sulfate)	**Premier choix** Neonatal meningitis Sepsis without septic shock Sepsis without septic shock Sepsis without septic shock co-prescrite avec amoxicillin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescrite avec ampicillin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescrite avec ampicillin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] co-prescrite avec ampicillin Peritoneal abscess (mild-moderate) co-prescrite avec ampicillin Peritoneal abscess (severe) co-prescrite avec ampicillin Peritonitis (mild-moderate) co-prescrite avec ampicillin Peritonitis (severe) co-prescrite avec benzylpenicillin Acute malnutrition in infants, children or adolescents (complicated) [children] co-prescrite avec benzylpenicillin Bacterial pneumonia (Community-acquired pneumonia - severe) [children] **Second choix** Other specified prophylactic measures Gonococcal infection **Autres indications** Bacterial infection of unspecified site

Meticillin

Section	Indications
Access group antibiotics	**Premier choix** Therapeutic equivalent to cloxacillin pour Bacterial infection of joint Therapeutic equivalent to cloxacillin pour Osteomyelitis or osteitis Therapeutic equivalent to cloxacillin pour Bacterial cellulitis, erysipelas or lymphangitis **Second choix** Therapeutic equivalent to cloxacillin pour Sepsis without septic shock

Metronidazole

Section	Indications
Access group antibiotics ◦ Oral > Liquid: 200 mg per 5 mL (as benzoate) ◦ Local > Rectal > Suppository: 500 mg; 1 g ◦ Parenteral > General injections > unspecified: 500 mg per 100 mL in vial ◦ Oral > Solid > tablet: 200 mg; 250 mg; 400 mg; 500 mg ◦ Oral > Solid > tablet: 500 mg; 200 mg; 250 mg; 400 mg ◦ Oral > Solid: 200 to 500 mg tablet ◦ Parenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection	**Premier choix** Trichomoniasis Intestinal infections due to Clostridioides difficile Necrotising fasciitis co-prescrite avec cefazolin Other specified prophylactic measures co-prescrite avec cefotaxime Peritoneal abscess (mild-moderate) co-prescrite avec cefotaxime Peritoneal abscess (severe) co-prescrite avec cefotaxime Peritonitis (mild-moderate) co-prescrite avec cefotaxime Peritonitis (severe) co-prescrite avec ceftriaxone Peritoneal abscess (mild-moderate) co-prescrite avec ceftriaxone Peritoneal abscess (severe) co-prescrite avec ceftriaxone Peritonitis (mild-moderate) co-prescrite avec ceftriaxone Peritonitis (severe) **Second choix** co-prescrite avec ciprofloxacin Peritoneal abscess (mild-moderate) co-prescrite avec ciprofloxacin Peritonitis (mild-moderate) **Autres indications** Bacterial infection of unspecified site

Nafcillin

Section	Indications
Access group antibiotics	**Premier choix** Therapeutic equivalent to cloxacillin pour Bacterial infection of joint Therapeutic equivalent to cloxacillin pour Osteomyelitis or osteitis Therapeutic equivalent to cloxacillin pour Bacterial cellulitis, erysipelas or lymphangitis **Second choix** Therapeutic equivalent to cloxacillin pour Sepsis without septic shock

Nitrofurantoin

Section	Indications
Access group antibiotics ◦ Oral > Liquid: 25 mg per 5 mL oral liquid ◦ Oral > Solid > dosage form: 100 mg; 50 mg	**Premier choix** Infectious cystitis

Oxacillin

Section	Indications
Access group antibiotics	**Premier choix** Therapeutic equivalent to cloxacillin pour Bacterial infection of joint Therapeutic equivalent to cloxacillin pour Osteomyelitis or osteitis Therapeutic equivalent to cloxacillin pour Bacterial cellulitis, erysipelas or lymphangitis **Second choix** Therapeutic equivalent to cloxacillin pour Sepsis without septic shock

Phenoxymethylpenicillin

Section	Indications
Access group antibiotics ◦ Oral > Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid ◦ Oral > Solid: 250 mg (as potassium salt); 500 mg (as potassium salt) ◦ Oral > Solid: 250 mg (as potassium salt) tablet	**Premier choix** Bacterial pneumonia (Community-acquired pneumonia - mild to moderate) Periapical abscess without sinus Acute pharyngitis **Autres indications** Bacterial infection of unspecified site

Procaine benzylpenicillin

Section	Indications
Access group antibiotics ◦ Parenteral > General injections > IM: 1 g in vial (=1 million IU) powder for injection; 3 g in vial (=3 million IU) powder for injection	**Premier choix** Congenital syphilis [children] **Second choix** Syphilis

Spectinomycin

Section	Indications
Access group antibiotics ◦ Parenteral > General injections > unspecified: 2 g in vial (as hydrochloride) powder for injection	**Second choix** Gonococcal infection **Autres indications** Bacterial infection of unspecified site

Sulfamethoxazole + trimethoprim

Section	Indications
Access group antibiotics ◦ Parenteral > General injections > IV: 80 mg + 16 mg per mL in 10 mL ampoule; 80 mg + 16 mg per mL in 5 mL ampoule ◦ Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid ◦ Oral > Solid: 100 mg + 20 mg tablet; 400 mg + 80 mg tablet; 800 mg + 160 mg tablet ◦ Oral > Solid > dispersible tablet: 100 mg + 20 mg ◦ Parenteral > General injections > IV: 80 mg + 16 mg per mL in 5 mL ampoule; 80 mg + 16 mg per mL in 10 mL ampoule	**Premier choix** Infectious cystitis **Second choix** Infectious gastroenteritis or colitis without specification of infectious agent **Autres indications** Bacterial infection of unspecified site

Tetracycline

Section	Indications
Access group antibiotics ◦ Oral > Solid: 250 mg (hydrochloride)	Bacterial infection of unspecified site

Trimethoprim

Section	Indications
Access group antibiotics ◦ Oral > Liquid: 50 mg per mL ◦ Oral > Solid: 100 mg; 200 mg	**Premier choix** Infectious cystitis